Molecular[®] Human Prekallikrein Total Antigen ELISA Kit Catalog # HPKKT-TOT Strip well format. Reagents for up to 96 tests. Rev:December 2016

www.mol-innov.com

INTENDED USE

This human prekallikrein total antigen assay is intended for the quantitative determination of total prekallikrein antigen in human plasma. For research use only.

BACKGROUND

Prekallikrein is the glycosylated single chain zymogen precursor of the plasma serine protease kallikrein. Plasma prekallikrein circulates with kininogen and is activated by Factor XIIa in the intrinsic coagulation pathway. Kallikrein activates plasminogen in fibrinolysis and cleaves kininogen in the bradykinin system of vasodilation. Prekallikrein deficiency is rare and causes increased activated partial thromboplastin time [1]. Elevated plasma prekallikrein is associated with diabetes [2] and cardiovascular disease [3].

ASSAY PRINCIPLE

Human prekallikrein will bind to the monoclonal capture antibody coated on the microtiter plate. Prekallikrein and kallikrein will react with the antibody on the plate. appropriate washing steps, anti-human After prekallikrein primary antibody binds to the captured protein. Excess primary antibody is washed away and bound antibody is reacted with peroxidase conjugated secondary antibody. Following an additional washing step, TMB substrate is used for color development at 450nm. A standard calibration curve is prepared along with the samples to be measured using dilutions of human prekallikrein. Color development is proportional to the concentration of total prekallikrein in the samples.

REAGENTS PROVIDED

- •96-well antibody coated microtiter strip plate (removable wells 8x12) containing anti-human prekallikrein antibody, blocked and dried.
- •10X Wash buffer: 1 bottle of 50ml
- •Human prekallikrein standard: 1 vial lyophilized standard
- •Anti-human prekallikrein primary antibody: 1 vial lyophilized polyclonal antibody
- secondary Anti-sheep horseradish peroxidase antibody: 1 vial concentrated HRP labeled antibody
- •TMB substrate solution: 1 bottle of 10ml solution

STORAGE AND STABILITY

Store all kit components at 4°C upon arrival. Return any unused microplate strips to the plate pouch with desiccant. Reconstituted standards and primary may be stored at -80°C for later use. Do not freeze-thaw the standard and primary antibody more than once. Store all other unused kit components at 4°C. This kit should not be used beyond the expiration date.

OTHER REAGENTS AND SUPPLIES REQUIRED

- •Microtiter plate shaker capable of 300 rpm uniform horizontally circular movement
- Manifold dispenser/aspirator or automated microplate washer
- Microplate reader capable of measuring absorbance at 450 nm
- Pipettes and Pipette tips
- Deionized or distilled water
- Polypropylene tubes for dilution of standard
- Paper towels or laboratory wipes
- 1N H₂SO₄ or 1N HCl
- •Bovine Serum Albumin Fraction V (BSA)
- Tris(hydroxymethyl)aminomethane (Tris) Sodium Chloride (NaCl)

PRECAUTIONS

- •FOR LABORATORY RESEARCH USE ONLY. NOT FOR DIAGNOSTIC USE.
- Do not mix any reagents or components of this kit with any reagents or components of any other kit. This kit is designed to work properly as provided.
- •Always pour peroxidase substrate out of the bottle into a clean test tube. Do not pipette out of the bottle as contamination could result.
- •Keep plate covered except when adding reagents, washing, or reading.
- •DO NOT pipette reagents by mouth and avoid contact of reagents and specimens with skin.
- •DO NOT smoke, drink, or eat in areas where specimens or reagents are being handled.

PREPARATION OF REAGENTS

•TBS buffer: 0.1M Tris, 0.15M NaCl, pH 7.4

•Blocking buffer (BB): 3% BSA (w/v) in TBS

•1X Wash buffer: Dilute 50ml of 10X wash buffer concentrate with 450ml of deionized water

SAMPLE COLLECTION

Collect plasma using EDTA or citrate as an anticoagulant. Centrifuge for 15 minutes at 1000xg within 30 minutes of collection. Assay immediately or aliquot and store at \leq -20°C. Avoid repeated freeze-thaw cycles.

ASSAY PROCEDURE

Perform assay at room temperature. Vigorously shake plate (300rpm) at each step of the assay.

Preparation of Standard

Reconstitute standard by adding 1ml of blocking buffer directly to the vial and agitate gently to completely dissolve contents. This will result in a 10μ g/ml standard solution.

Dilution table for preparation of human prekallikrein standard:

Prekallikrein concentration	Dilutions
(µg/ml)	
10	Straight from vial
5	500µl (BB) + 500µl (from vial)
2	600μl (BB) + 400μl (5μg/ml)
1	500μl (BB) + 500μl (2μg/ml)
0.5	500μl (BB) + 500μl (1μg/ml)
0.2	600µl (BB) + 400µl (0.5µg/ml)
0.1	500μl (BB) + 500μl (0.2μg/ml)
0.05	500μl (BB) + 500μl (0.1μg/ml)
0.02	600μl (BB) + 400μl (0.05μg/ml)
0	500µl (BB) Zero point to determine background

NOTE: DILUTIONS FOR THE STANDARD CURVE AND ZERO STANDARD MUST BE MADE AND APPLIED TO THE PLATE IMMEDIATELY.

Standard and Unknown Addition

Remove microtiter plate from bag and add 100µl prekallikrein standards (in duplicate) and unknowns to wells. Carefully record position of standards and unknowns. Shake plate at 300rpm for 30 minutes. Wash wells three times with 300µl wash buffer. Remove excess wash by gently tapping plate on paper towel or kimwipe.

NOTE: The assay measures human prekallikrein antigen in the 0.02-10 μ g/ml range. If the unknown is thought to have high prekallikrein levels, dilutions may be made in blocking buffer. Normal human plasma should be applied directly to the plate or at a 1:5 dilution for best results.

Primary Antibody Addition

Reconstitute primary antibody by adding 10ml of blocking buffer directly to the vial and agitate gently to completely dissolve contents. Add 100µl to all wells. Shake plate at 300rpm for 30 minutes. Wash wells three times with 300µl wash buffer. Remove excess wash by gently tapping plate on paper towel or kimwipe.

Secondary Antibody Addition

Briefly centrifuge vial before opening. Dilute 1μ l of conjugated secondary antibody in 10ml of blocking buffer and add 100 μ l to all wells. Shake plate at 300rpm for 30 minutes. Wash wells three times with 300 μ l wash buffer. Remove excess wash by gently tapping plate on paper towel or kimwipe.

Substrate Incubation

Add 100µl TMB substrate to all wells and shake plate for 2-10 minutes. Substrate will change from colorless to different strengths of blue. Quench reaction by adding 50µl of $1N H_2SO_4$ or HCl stop solution to all wells when samples are visually in the same range as the standards. Add stop solution to wells in the same order as substrate upon which color will change from blue to yellow. Mix thoroughly by gently shaking the plate.


Measurement

Set the absorbance at 450nm in a microtiter plate spectrophotometer. Measure the absorbance in all wells at 450nm. Subtract zero point from all standards and unknowns to determine corrected absorbance (A_{450}).

Calculation of Results

Plot A₄₅₀ against the amount of prekallikrein in the standards. Fit a straight line through the linear points of the standard curve using a linear fit procedure if unknowns appear on the linear portion of the standard curve. Alternatively, create a standard curve by analyzing the data using a software program capable of generating a four parameter logistic (4PL) curve fit. The amount of prekallikrein in the unknowns can be determined from this curve. If samples have been diluted, the calculated concentration must be multiplied by the dilution factor.

A typical standard curve (EXAMPLE ONLY):



EXPECTED VALUES

Prekallikrein is present in normal human plasma at concentrations of 15μ g/ml [4] to 55μ g/ml [5] as determined by clotting assay. Prekallikrein antigen measured by ELISA has not been reported.

PERFORMANCE CHARACTERISTICS

Sensitivity: The minimum detectable dose (MDD) was determined by adding two standard deviations to the mean optical density value of twenty zero standard replicates (range OD450: 0.098-0.107) and calculating the corresponding concentration. The MDD was 0.012µg/ml.

Intra-assay Precision: These studies are currently in progress. Please contact us for more information.

Inter-assay Precision: These studies are currently in progress. Please contact us for more information.

Recovery: These studies are currently in progress. Please contact us for more information.

Linearity: These studies are currently in progress. Please contact us for more information.

Specificity: These studies are currently in progress. Please contact us for more information.

Specificity: Samples were evaluated for the presence of the antigen at varying dilutions.

DISCLAIMER

This information is believed to be correct but does not claim to be all-inclusive and shall be used only as a guide. The supplier of this kit shall not be held liable for any damage resulting from handling of or contact with the above product.

REFERENCES

- 1. Sollo DG and Saleem A: Ann Clin Lab Sci. 1985, 15:279-285.
- 2. Jaffa AA et al.: Diabetes. 2003, 52:1215-1221.
- 3. Mackenzie JA *et al*.: Appl Physiol Nutr Metab. 2010, 35:518-525.
- 4. Heimark RL and Davie EW: Methods Enzymol. 1981, 80(Pt C):157-172.
- 5. Bouma AA et al.: Biochemistry. 1980, 19:1151-1160.

Example of ELISA Plate Layout 96 Well Plate: 20 Standard wells, 76 Sample wells

A 0 0.02 0.05 0.1 0.2 0.5 1 2 5 10 B 0 0.02 0.05 0.1 0.2 0.5 1 2 5 10 C 0 µg/ml µg/ml µg/ml µg/ml µg/ml µg/ml µg/ml µg/ml C 0 0.02 0.05 0.1 0.2 0.5 1 2 5 10 B 0 µg/ml	Α	1	2	3	4	5	6	7	8	9	10	11	12
μg/ml μg/ml <t< th=""><th></th><th>0</th><th></th><th></th><th></th><th></th><th></th><th></th><th></th><th></th><th></th><th></th><th></th></t<>		0											
B U μg/ml μg/ml<	-		μg/ml	μg/ml	μg/ml	µg/ml	µg/ml	μg/ml 1	µg/ml	µg/ml	μg/ml		
C C C C C C C C C C C C C C C C C C C	В	0				ug/ml			2 ug/ml				
E F G	с							5		5			
F G 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	D									19	/	G	
G	E												
	F				\mathbf{D}		•	V)					
	G			~ 1									
Refercific Ins	н							C					
lotspe			SP	e	er								